Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024 07:35 ET
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers...
Lilium Reaffirms 2026 Target for First Customer Deliveries and Provides Additional Detail on Testing Program
July 17, 2024 07:30 ET
|
Lilium GmbH
First aircraft (Lilium Jet MSN 1) to be used exclusively for ground testing starting in a few weeksSecond aircraft (Lilium Jet MSN 2) to be used for first manned flight in early 2025, will start...
Guardforce AI Expands Contracts with Two Major Retail Customers
July 17, 2024 07:30 ET
|
Guardforce AI Co., Ltd.
Increases business footprint to nearly 20,000 retail stores across Asia Pacific New services include smart retail solutions to enhance store efficiency New York, NY, July 17, 2024 ...
Enovix to Release Second Quarter 2024 Financial Results on July 31, 2024
July 17, 2024 07:30 ET
|
Enovix Corporation
FREMONT, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), a global high-performance battery company, today announced it will release financial results for the...
Cellebrite Advances Plans to Transform and Elevate its Strategic Relationship with the U.S. Federal Government
July 17, 2024 07:30 ET
|
Cellebrite DI Ltd
TYSONS CORNER, Va. and PETAH TIKVA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a leader in digital investigative solutions for the public and private sectors, officially...
Gauzy’s Advanced Driver Assistance Systems (ADAS) Enhances Public Safety at the 2024 Paris Olympics With More Than 11 Million Expected Visitors
July 17, 2024 07:30 ET
|
GAUZY LTD
TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Gauzy Ltd. (Nasdaq: GAUZ) (“Gauzy” or the “Company”), a leading developer and manufacturer of Advanced Driver Assistance Systems (ADAS), today...
ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation
July 17, 2024 07:25 ET
|
ASLAN PHARMACEUTICALS LIMITED
Following a thorough review of all strategic alternatives, ASLAN Pharmaceuticals Pte Ltd, the sole operating subsidiary of ASLAN Pharmaceuticals, has filed for voluntary liquidation Quantuma...
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
July 17, 2024 07:25 ET
|
ALTERITY THERAPEUTICS LIMITED
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated...
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
July 17, 2024 07:15 ET
|
Opthea Limited
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
July 17, 2024 07:07 ET
|
SciSparc Ltd
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...